RT Journal Article
T1 Underlying heart diseases and acute COVID-19 outcomes.
A1 Núñez-Gil, Iván J
A1 Fernández-Ortiz, Antonio
A1 Maroud Eid, Charbel
A1 Huang, Jia
A1 Romero, Rodolfo
A1 Becerra-Muñoz, Victor Manuel
A1 Uribarri, Aitor
A1 Feltes, Gisela
A1 Trabatoni, Daniela
A1 Fernandez-Rozas, Inmaculada
A1 Viana-Llamas, Maria C
A1 Pepe, Martino
A1 Cerrato, Enrico
A1 Bertaina, Maurizio
A1 Capel Astrua, Thamar
A1 Alfonso, Emilio
A1 Castro-Mejía, Alex F
A1 Raposeiras-Roubin, Sergio
A1 D'Ascenzo, Fabrizio
A1 Espejo Paeres, Carolina
A1 Signes-Costa, Jaime
A1 Bardaji, Alfredo
A1 Fernandez-Pérez, Cristina
A1 Marin, Francisco
A1 Fabregat-Andres, Oscar
A1 Akin, Ibrahim
A1 Estrada, Vicente
A1 Macaya, Carlos
K1 COVID-19
K1 cardiology
K1 heart disease
K1 mortality
K1 prognosis
K1 registry
AB The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from hospital, dead or alive. HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, cerebrovascular disease and oncologic antecedents (p  An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19. Its presence could be related with different clinical drug management and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers during in-hospital stay.
YR 2020
FD 2020-12-21
LK http://hdl.handle.net/10668/16827
UL http://hdl.handle.net/10668/16827
LA en
DS RISalud
RD Apr 10, 2025